Literature DB >> 15501204

Pulmonary hypertension in sickle cell disease.

Kenneth I Ataga1, Namita Sood, Guy De Gent, Eileen Kelly, Ashley G Henderson, Susan Jones, Dell Strayhorn, Alice Lail, Susan Lieff, Eugene P Orringer.   

Abstract

BACKGROUND: Recurrent vaso-occlusive episodes lead to progressive end-organ damage in patients with sickle cell disease. We sought to determine the prevalence of pulmonary hypertension in adult patients with sickle cell disease and to identify factors associated with this life-threatening complication.
METHODS: Sixty patients (> or =18 years of age; mean [+/- SD] age, 37 +/- 13 years) followed at a University Medical Center were evaluated. They were selected by a systematic sampling of patients presenting to the clinic for routine follow-up visits. All enrolled subjects underwent a clinical examination, Doppler echocardiography, pulmonary function tests, and hematologic tests during a single visit. Pulmonary hypertension was defined using an age- and body mass index-adjusted nomogram.
RESULTS: The prevalence of pulmonary hypertension was 30% (18/60). Ten patients had mild pulmonary hypertension (up to 44 mm Hg), 5 had moderate pulmonary hypertension (45 to 74 mm Hg), and 2 had severe pulmonary hypertension (> or =75 mm Hg). In a logistic regression model, both lower fetal hemoglobin level and lower systolic blood pressure were associated with the presence of pulmonary hypertension.
CONCLUSION: We found that the prevalence of pulmonary hypertension in adult patients with sickle cell disease was substantial, particularly in those with lower levels of fetal hemoglobin and lower systolic blood pressure.

Entities:  

Mesh:

Year:  2004        PMID: 15501204     DOI: 10.1016/j.amjmed.2004.03.034

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  40 in total

Review 1.  Vasculopathy and pulmonary hypertension in sickle cell disease.

Authors:  Karin P Potoka; Mark T Gladwin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-11-14       Impact factor: 5.464

2.  Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies.

Authors:  Robyn J Barst; Kamal K Mubarak; Roberto F Machado; Kenneth I Ataga; Raymond L Benza; Oswaldo Castro; Robert Naeije; Namita Sood; Paul S Swerdlow; Mariana Hildesheim; Mark T Gladwin
Journal:  Br J Haematol       Date:  2010-02-17       Impact factor: 6.998

3.  Hemolysis-associated pulmonary hypertension in thalassemia.

Authors:  Claudia R Morris; Frans A Kuypers; Gregory J Kato; Lisa Lavrisha; Sandra Larkin; Titi Singer; Elliott P Vichinsky
Journal:  Ann N Y Acad Sci       Date:  2005       Impact factor: 5.691

4.  Amplified expression profiling of platelet transcriptome reveals changes in arginine metabolic pathways in patients with sickle cell disease.

Authors:  Nalini Raghavachari; Xiuli Xu; Amy Harris; Jose Villagra; Carolea Logun; Jennifer Barb; Michael A Solomon; Anthony F Suffredini; Robert L Danner; Gregory Kato; Peter J Munson; Sidney M Morris; Mark T Gladwin
Journal:  Circulation       Date:  2007-03-12       Impact factor: 29.690

5.  Diastolic dysfunction is an independent risk factor for death in patients with sickle cell disease.

Authors:  Vandana Sachdev; Roberto F Machado; Yukitaka Shizukuda; Yesoda N Rao; Stanislav Sidenko; Inez Ernst; Marilyn St Peter; Wynona A Coles; Douglas R Rosing; William C Blackwelder; Oswaldo Castro; Gregory J Kato; Mark T Gladwin
Journal:  J Am Coll Cardiol       Date:  2007-01-16       Impact factor: 24.094

Review 6.  Pulmonary hypertension associated with sickle cell disease: pathophysiology and rationale for treatment.

Authors:  Raymond L Benza
Journal:  Lung       Date:  2008-05-10       Impact factor: 2.584

7.  Cardiopulmonary complications of sickle cell disease: role of nitric oxide and hemolytic anemia.

Authors:  Mark T Gladwin; Gregory J Kato
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2005

8.  Racial and Ethnic Differences in Pediatric Pulmonary Hypertension: An Analysis of the Pediatric Pulmonary Hypertension Network Registry.

Authors:  Mei-Sing Ong; Steve Abman; Eric D Austin; Jeffrey A Feinstein; Rachel K Hopper; Usha S Krishnan; Mary P Mullen; Marc D Natter; J Usha Raj; Erika B Rosenzweig; Kenneth D Mandl
Journal:  J Pediatr       Date:  2019-06-05       Impact factor: 4.406

9.  Novel small molecule therapeutics for sickle cell disease: nitric oxide, carbon monoxide, nitrite, and apolipoprotein A-I.

Authors:  Gregory J Kato
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2008

Review 10.  Pleiotropic effects of intravascular haemolysis on vascular homeostasis.

Authors:  Gregory J Kato; James G Taylor
Journal:  Br J Haematol       Date:  2009-12-01       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.